Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis

Journal of the American College of Cardiology

Volumn 39, Issue 7, 2002, Pages 1151-1158

  Allman, Kevin C ^a   Shaw, Leslee J ^b   Hachamovitch, Rory ^b   Udelson, James E ^c  

^a Department of Microbiology and Infectious Diseases   (Australia)

^b Atlanta Cardiovasc Res Institute   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOBUTAMINE; FLUORODEOXYGLUCOSE F 18; THALLIUM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE; HEART MUSCLE REVASCULARIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

CORONARY DISEASE; DOBUTAMINE; ECHOCARDIOGRAPHY; FEMALE; FLUORODEOXYGLUCOSE F18; HEART; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL REVASCULARIZATION; PROGNOSIS; RADIOPHARMACEUTICALS; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0037012432     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(02)01726-6     Document Type: Article

References (44)

1. Current medical therapy for advanced heart failure
2. Coronary bypass surgery, for chronic angina - 1981: A perspective
3. Reversible ischemic left ventricular dysfunction: Evidence for the "hibernating" myocardium
4. Accuracy of currently available techniques for prediction of functional recovery, after revascularization in patients with left ventricular dysfunction due to chronic coronary artery, disease: Comparison of pooled data
5. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy
6. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability
7. Noninvasive assessment of myocardial viability
8. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography
9. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: Comparison with stress thallium imaging
10. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality, with and without revascularization
11. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction
12. Myocardial viability assessment in ischemic cardiomyopathy: Benefits of coronary revascularization
13. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction: Relative efficacy of medical therapy and revascularization
14. Prognostic value of rest-redistribution tomographic thallium-201 imaging in ischemic cardiomyopathy
15. Prognostic value of tomographic rest-redistribution thallium 201 imaging in medically treated patients with coronary artery disease and left ventricular dysfunction
16. Prognostic value of dobutamine echocardiography in patients with left ventricular dysfunction
17. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease
18. Improved outcome after coronary bypass surgery in patients with ischemic cardiomyopathy and residual myocardial viability
19. Incremental prognostic value of thallium reinjection after stress-redistribution imaging in patients with previous myocardial infarction and left ventricular dysfunction
20. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease
21. Myocardial viability during dobutamine echocardiography predicts survival in patients with coronary artery disease and severe left ventricular systolic dysfunction
22. Prognostic value of detection of myocardial viability using low-dose dobutamine echocardiography in infarcted patients
23. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging
24. Successful coronary revascularization improves prognosis in patients with previous myocardial infarction and evidence of viable myocardium at thallium-201 imaging
25. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: Implications for the role of myocardial viability assessment in management decisions
26. Predictive value of planar 18F-fluorodeoxyglucose imaging for cardiac events in patients after acute myocardial infarction
27. Prognostic value of the amount of dysfunctional but viable myocardium in revascularized patients with coronary artery disease and left ventricular dysfunction: Investigators of this multicenter study
28. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure
29. Coronary artery bypass surgery as treatment for ischemic heart failure: The predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome
30. Improvement of left ventricular ejection fraction, heart failure symptoms and prognosis after revascularization in patients with chronic coronary artery disease and viable myocardium detected by dobutamine stress echocardiography
31. Prognostic value of myocardial ischemia and viability in patients with chronic left ventricular ischemic dysfunction
32. Myocardial viability on echocardiography predicts long-term survival after revascularization in patients with ischemic congestive heart failure
33. Dobutamine-atropine stress echocardiography for risk stratification in patients with chronic left ventricular dysfunction
34. Meta-analysis in clinical trials
35. Prognostic value of angiographic indices of coronary artery disease from the Coronary Artery Surgery Study (CASS)
36. Comparison of coronary artery bypass surgery and medical therapy in patients 65 years of age or older: A nonrandomized study from the Coronary Artery Surgery Study (CASS) registry
37. Comparison of effects of medical and surgical therapy on survival in severe angina pectoris and two-vessel coronary artery disease with and without left ventricular dysfunction: A Coronary Artery Surgery Study Registry study
38. Management of heart failure. III. The role of revascularization in the treatment of patients with moderate or severe left ventricular systolic dysfunction
39. Surgical survival benefits for coronary disease patients with left ventricular dysfunction
40. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy
41. The effect of spironolactone on morbidity and mortality in patients with severe heart failure: Randomized Aldactone Evaluation study investigators
42. Acute coronary findings at autopsy in heart failure patients with sudden death: Results from the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial
43. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: A prospective, randomized comparison of patients with suspicion of jeopardized myocardium
44. Failure to improve left ventricular function after coronary revascularization for ischemic cardiomyopathy is not associated with worse outcome